SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of Shareholders
SCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKind
SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders
Shareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public Shareholders
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111
scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript
scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates
scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025
scPharmaceuticals Inc. (SCPH) Q1 2025 Earnings Call Transcript
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates
scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025
scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences
scPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call Transcript
ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?
scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences
scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
scPharmaceuticals Inc. (SCPH) Q3 2024 Earnings Call Transcript
ScPharmaceuticals, Inc. (SCPH) Reports Q3 Loss, Lags Revenue Estimates
scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update
scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024
Does scPharmaceuticals (SCPH) Have the Potential to Rally 291.9% as Wall Street Analysts Expect?
scPharmaceuticals Inc. (SCPH) Q2 2024 Earnings Call Transcript
ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates
scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
scPharmaceuticals Announces Pricing of $50.0 Million Public Offering
scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure
scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector
scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
7 Short-Squeeze Stocks That Could Beat Down the Bears
scPharmaceuticals to Present at the Jefferies Global Healthcare Conference
scPharmaceuticals Inc. (SCPH) Q1 2024 Earnings Call Transcript
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates
scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024
scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection